Immatics N.V.
Business
Immatics N.V. is a clinical-stage biotechnology company developing T cell receptor (TCR)-based immunotherapies for patients with solid tumors. It offers two core therapeutic modalities: autologous engineered TCR-T cell therapies (ACTengine) and off-the-shelf antibody-like TCR bispecifics (TCER), supported by proprietary discovery and engineering platforms (XPRESIDENT, XCEPTOR, XCUBE). Key business activities include discovery, preclinical and clinical development, manufacturing scale-up for cell therapies, and strategic collaborations and partnerships. Its programs are developed and distributed through clinical trial networks, specialized academic centers, standard pharmaceutical supply chains, and planned commercial channels in the United States and Europe.
Summary from filing dated 2025-03-27
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-196.45M |
| Total assets | $562.34M |
| Total liabilities | — |
| Stockholders' equity | — |
| Operating cash flow | — |